

UNITED STATES

28 Have

NUCLEAR REGULATORY COMMISSION

REGIONIV

611 RYAN PLAZA DRIVE, SUITE 400 ARLINGTON, TEXAS 76011-8064

JAN 14 1994

MEMORANDUM FOR:

John E. Glenn, Chief Medical, Academic, and Commercial Use Safety Branch Division of Industrial & Medical Nuclear Safety Office of Nuclear Material Safety and Safeguards

FROM:

Dwight Chamberlain, Acting Director Division of Radiation Safety and Safeguards Region IV

SUBJECT;

REVIEW OF LICENSE FILES FOR RECORDS TO RESEARCH INVOLVING HUMAN SUBJECTS

This memorandum responds to your request for Region IV to conduct a review of license docket files selected by the licensing and inspection staff based on the criteria provided in your E-mail memo of January 10, 1994. The principal focus of our review was to determine if medical or scientific radiation effects research in humans, other than for radiopharmaceutical development, had been conducted prior to the dissolution of the Atomic Energy Commission (AEC) in 1975. The following licensees were selected from those licenses currently or previously authorized in the LAN data base for human research and in conjunction with the collective memories of our licensing and inspection staffs of their early respective licensed activities. All available licenses, license backup documents, and inspection reports were reviewed.

LICENSE NO.
42-00220-06
03-01082-01
42-00084-06
05-01401-02

9402230315 940204 PDR DR0 NE ED PDR

John E. Glenn

LICENSEE	LICENSE NO.
The Mark State of the State	
Department of the Army	
William Beaumont Army Medical Center	42-05255-07
Fitzsimmons Army Medical Center	05-00046-13
Brocke Army Medical Center	42-01368-01
State of Oklahoma	
University of Oklahoma Health Sciences Center	35-03176-01
Oklahoma Medical Research Foundation	35-07464-03
National Aeronautics & Space Administration	42-09388-03

The attached enclosures provide a summary of the available information contained in each docket file reviewed. It should be noted that information reviewed was sketchy, large gaps of information appeared to be missing, and the compressed time scheduled for review increased the potential for oversight of other human research activities addressed in your memo. In addition, a number of these licensees were authorized for Atomic Number 3-83 for the broad category of human research and, therefore, all types of human research cannot be easily clarified through a limited file review. It is conceivable that additional review could reveal other interesting information.

In reviewing the docket files, no specific incidence of deliberate exposure to the public using special nuclear material or transuranics were noted. However, we noted specific instances in which informed volunteers from a penitentiary, mental health hospital, VA hospital, and a military facility were utilized in human research. Other uses of byproduct materials, other than in support of radiopharmaceutical research in humans, included metabolic studies, nutrition studies, and treatment or diagnosis of rare diseases.

-2-

John E. Glenn

If you wish to discuss the above comments or require additional information, please contact Mr. Jack Whitten of my staff at FTS (817)860-8197 or Ms. Vivian Campbell at FTS (817) 860-8143.

any ampel Dwight Chamberlain, Acting Director Division of Radiation Safety

and Safeguards

Enclosure: As stated

Licensee: Department of Veterans Affairs Dallas, Texas License No.: 42-00220-06 issued 4/22/58 Supersedes License No. 42-220-2, issued 5/17/56 Docket No.: 030-03256

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
51	5/23/72	S-35	sulfate			Metabolism studies in 25 patients in accordance with protocol submitted in letter dated Nov. 2, 1971	11/2/71
36	3/1/68	Fe-55	Ferric chloride			Study iron absorption by double isotope labeling technique. Normal (volunteers) and patients with various problems of iron metabolism	11/8/67
32	1/4/67	I-131	Triiodothyronine			Invivo studies in thyroid function in 10 patients	11/3/66
		Cr-51	chloride			Cardiac output studies in 10 patients	
		S-35	sulphate			Determination of extracelluiar fluid volume in 10 patients	
		Hg-197	mercurihydroxypropane			Spleen scans on 20 adult patients	
31	6/7/66	Hg-197	Mercurihydroxypropane			Spleen scans on 20 adult patients.	6/7/66
27	4/22/65	S-35	sulphate			Evaluation of simultaneous red cell mass & extracellular fluid volume measurements as a useful clinical procedure before, during & after major surgery	

18	1/26/62	Cr-51	Labeled Albumin	Study gastrointestinal protein loss	12/28/61
12	10/17/6	I-131	Polyvinylpyrolidine	Plasma volume measurements	9/28/60
4	9/3/59	Н-3	Water	Total body water determinations	8/17/59
2	2/9/59	I-131	Thyroxine or ACTH	Studies of thyroxine & ACTH binding in terminal cancer patients	1/21/59
0	4/22/58	I-131	Insulin	Studies of insulin binding and glucose uptake in terminal cancer patients	
		I-131	Triolein or Oleic acid	Studies of pancreatic function	
		Fe-59	chloride, citrate, or globulin complex	Studies of red cell production	
		Cr-51	Chromic chloride	Determination of blood volume & life of erythrocytes	
		C-14	Dextran	Determination of blood volumes	
		Na-24	chloride	Determination of sodium space	
		K-42	chloride	Determination of potassium space	

NOTE: Supporting documents not available for review.

Licensee: Department of Veterans Affairs Little Rock, Arkansas License No.: 03-01082-01, issued September 30, 1956 Docket No.: 030-01212

Amend No. or other Documentation	Date Issued	Isotope	Chemical form	Dose	ΡI	Purpose	Date of supporting document
0	9/30/56	H-3 Fe-59	Triated Water Citrate	100 mCi 2 mCi	Not specified Not specified	Water metabolism in normals and patients with congestive heart failure. Determine plasma iron turnover rates in normals and patients with various anemias and polycythemia.	None
Inspection Report 8/16/60		H-3	Water	50 mCi	Not specified	Water metabolism in normal patients and in patients with emphysema and congestive heart	None
		H-3	Cholesterol or Cholesteroles ters	100 mCi	Not specified	failure Cholesterol metabolism in normal patients and those	None
		H-3	Digoxin or digitoxin	100 mCi	Not specified	with atherosulerosis	None
						Metabolism of cardiac glycosides in normal patients and those with congestive heart failure	
Inspection Rep	ort	H-3	Not specified	120-150 µCi	Dr. Doherty	Metabolism	None
4/20/66		H-3	Collestrol	300 µCi	Not specified	Collestrol	None

17	9/9/66	3-83	Any	12 mCi	Not specified	Medical research, diagnosis, & therapy	None
23	5/5/72	S-35	Sodium sulfate	200 mCi Administered IV 8 times over 16 months	Not specified	Clinical diagnosis, therapy, & biomedical research. Therapy for chondrosarcoma	License renewal coplication dated 8/30/73

Licensee: Department of Veterans Affairs Houston, Texas

License No.: 42-00084-06, issued 4/3/58

Amendment No. 01 supersedes License No. 42-84-3 issued 2/7/57, 42-84-4 issued 4/8/57, and 42-84-5 issued 12/24/57

Docket No .:

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
24	2/28/66	Cr-51	Labeled Human serum albumin			Gastrointestinal protein loss studies	
18	1/27/64	H-3	Cortisol or cortisone			Steroid metabolism studies in patients over 40 years of age with cirrhosis of the liver	
17	1/13/64	C-14	2-C-14-5- Hydroxy- DL- Tryptophan			Used in determinations of production rate & pool size of serotonin in patients with functioning & non- functioning malignant carcinoid tumors	11/18/63
16	4/15/63	Na-24	chloride			Sodium space studies	4/9/63
13	2/25/63	C-14	Uracil mustard			Metabolism studies in patients with disseminated cancer	11/21/62
12	12/27/62	C-14	Serotonin			Used to determine human platelet survival .	10/10/62
		C-14	Uric acid			Used to study uric acid body pools & turnover rate in leukemia	
10	8/30/62	Ba-131	Barium sulfate			As an inert indicator in intestinal absorption studies	6/7 and 8/6/62
9	5/8/62	Н-3	Tritiated thymidine			Study of growth rates in neoplastic tissue	4/25/62

4	3/22/60	I-131	Renal function compounds	Renal function studies & renal scanning in 10 patients with known malignancies. Determination of circulation time.	3/4/60
3	8/21/59	I-131	Diodrast	Renal function studies & renal scanning studies in 10 patients with known malignancies	
1	1/29/59	Rb-86	chloride	Potassium exchange & red cell volume determinations	12/23/58
		K=42	chloride	Potassium exchangeable determinations	
		Fe-59	citrate	Iron plasma clearance and iron utilization	
		I-131	Triolein or Oleic acid	Fat absorption studies	
		I-131	L- thyroxine & homologs	L-thyroxine determinations following thyroidectomy	
0	4/3/58	I-131	Triolein or Oleic acid	Determination of pancreatic & intestinal function	
		Br-82	Bromide	Determination of extracellular fluid volume	

NOTE: 1) Amendment No. 26, issued 10/7/66: format change to broad authorization for medical research, diagnosis, & therapy. Unable to identify specific uses.

2) No supporting documentation available for review.

Licensee: Department of Veterans Affairs Denver, Colorado License No.: 05-01401-02, issued April 29, 1958 Supersede License No. 5-1401-1, issued March 21, 1956 Docket No.: No docket no. identified

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
18	6/4/65	H-3	Tritiated water	2mCi	H.Elrick, A.L.Daywitt, W.S.Keyting	Total body water determinations	4/7/65
13	10/25/62	Fe-59	Chloride, sulfate, citrate, globulin	2-5uCî	H.Elrick	For determining the mechanisms or estimating the status of erythropoiesis and/or iron metabolism in normal or diseased persons	10/10/62
12	12/21/61	Br-82	Potassium bromide	50uCi, orally	H.Elrick	APPLICATION REQUESTED HUMAN USE; HOWEVER LICENSE AUTHORIZED LABORATORY ANIMALS. For labeling of fat in fat absorption studies	10/10/62
11	11/28/61	Br-77	Potassium bromide	50uCi, orally	H.Elrick	APPLICATION REQUESTED HUMAN USE; HOWEVER LICENSE AUTHORIZED LABORATORY ANIMALS. For labeling of fat in fat absorption studies	11/14/61
6	8/31/60	Ca-47	chloride	50uCi	H.Elrick	To study metabolism of Ca-47 in man: absorption. Uptake in bones. Disappearance from blood & excretion in urine and feces	7/20&21/60
4	12/14/59	I-131	insulin	50uCi, parente rally	H.Elrick	Metabolism of insulin-I- 131 in normal, thyroid, renal, liver and pancreatic diseases	11/25/59

							And the second
3	12/8/58	I-131	Diodrast	25uCi,I V	H.Elrick	Study of dynamic function of individual kidneys in patients with hypertension	11/17/58
0	4/29/58	I-131	Trielein	50- 70uCi	H.Elrick	To study fat absorption	3/31/58
0	4/29/58	C-14	glucose	100uCi	H.Elrick	Study of effect of hormones on carbohydrate	3/31/58
0	4/29/58	Na-24	chloride	100uCi	H.Elrick	Determination of sodium space	3/31/58
Ō	4/29/58	K-42	carbonate	100uCi	H.Elrick	Determination of potassium	3/31/58
0	4/29/58	Fe-59	Ferric chloride	100uCi	H.Elrick	Determination of red cell formation	3/31/58
0	4/29/58	I-131	Glucagon	5mCi Maximum possess ion		Tracer studies with glucagon in patients with limited life expectancy	Apparently approved on 05- 1401-1, no supporting documentation available
0	4/29/58	Silver- 110	Any	20mCi Maximum possess ion		Determination of plasma chloride concentration	Apparently approved on 05- 1401-1, no supporting documentation available

NOTE: Based on review of file, it appears that VA-Denver buried radioactive waste in Denver Land Fill, 19 miles SE of hospital.

Licensee: Department of Army William Beaumont Medical Center El Paso, Texas License No.: 42-05255-07, issued September 24, 1964 Docket No.: 030-03260

Amend No. or other Documentation	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
19	5/18/71	Ca-47	Chloride	30 µCi	Not specified	Calcium absorption studies in 1 patient in accordance with application dated 4/27/71	Application dated 4/27/71
22	10/1/71	F-18	Fluoride	0.5-4 mCi 25 patients	Not specified	Bone imaging	Application dated 7/29/71
25	3/7/72	F-18	Fluoride	0.5-4 mCi Additional 100 patients	Not specified	Bone imaging	Application dated 7/29/71
Inspection Rep	ort 3/10/67			30-40 µCi 2 studies each at the beginning/ middle/end of each study	Not specified	Repetitive cardiac output determinations in normal volunteers. Ages 30-45.	None

Licensee: Department of the Army Fitzsimons Army Medical Center Aurora, Colorado

License No.: 05-00046-13, issued 2/3/64

Docket No.: 030-01233

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
23	5/28/71	Se-75	Selenite			Determine site & nature of selenium protein bond in 25 cancer patients plasma to evaluate nutritional liver disease	1/5/71
22	4/26/71	C-14	Glucose		CPT Raym ond Burk	Study of glucose metabolism in 24 normal male volunteers at Fort Sam Houston, TX and at Summit of Pikes Peak, Colorado	1/5/71
16	5/15/69	C-14	Glucose		CPT Shaf eek Sanb ar	Study of glucose metabolism in 8 normal male volunteers at the summit of Pike's Peak, Colorado and in 8 normal male volunteers at Fort Sam Houston, TX	
11	9/15/67	C-14	4-C14-cortisol, 1,2-H3- aldosterone			Use in 10 volunteers to study effects of high altitude on man	7/13/67
9	3/24/67	C-14	Vitamins, carbohydrates, amino acids, lipids, acetate			Metabolic & physiological tracer studies in volunteers	11/18/66
		H-3	Vitamins, Water				

		Mg-28	Oxide, chloride, citrate	
		Ca-45	chloride	
		Ca-47	chloride	
1	7/31/64	C-14	Vitamins, amino acids, lipids, acetate, carbohydrates, mevalonic acid, bicarbonate or carbon dioxide	Nutrítion & metabolism tracer studies
		H-3	Vitamins	
		Mg-28	Oxide, chloride, citrate	
		Ca-47	chloride	
		Ca-45	chloride	
0	2/3/64	I-131	Triolein or Oleic acid	Determination of fat absorption
		I-131	p-Toluidine polyvinylpyrrol idine	Determination of protein loss
		I-125	Triolein or Oleic acid	Determination of fat absorption
		I-125	Cholografin	Determination of liver & gallbladder function
		Fe-59	Ferric chloride, Ferrous citrate	Determination of iron turnover
		Н-3	Water	Determination of total body water
		Na-24	Sodium chloride	Determination of total exchangeable sodium

NOTE: Supporting documentation not available for review.

Licensee: Department of the Army Brooke Army Medical Center Ft. Sam Houston, Texas License No.: 42-01368-01, issued Nov. 5, 1956 Docket No.: 030-03258

Amend No.	Date Issued	Isotope	Chemical form	Maximum possession limit	PI*	Purpose	Date of supporting document**
23	3/6/68	S-35	Sodium sulfate	lOmCi		Study of the influences of sodium chloride intake on mineral metabolism and adrenocortical function during acclimatization to heat in 18 volunteers	12/8/67
		K-42	chloride	25mCi		ditto	ditto
		H-3	Water	25mCi		ditto	ditto
-		H-3	1,2-H3 aldosterone	257		ditto	ditto
14	4/7/64	Н-3	Water	25mCi		Determination of total body water	9/5/63
		Na-24	chloride	1mCi		Determination of total exchangeable sodium	ditto
		H-3	aldosterone	250mCi		Determination of aldosterone secretion rates	ditto
		C-14	hydrocortisone	50mCi		Determination of cortisol Secretion rates and plasma cortisol clearance	ditto
10	11/9/62	K-42	Potassium chloride	50mCi		leasurement of extra-cellular fluid compartment	8/1/62
8	10/31/60	K-42	Any	50mCi		Iron metabolism studies	9/1/60
		I-131	Labelled Fat	10mCi		Study of pancreatic function & intestinal malabsorption	ditto
6	6/14/60	I-131	Hypaque	2uCi		Kidney function test	9/30/59
5	11/24/59	1-131	Diodrast	10mCi		Kidney function test	9/30/59
3	8/6/57	I-131	Triolein and/or Oleic acid	10mCi		Study of pancreatic function & intestinal malabsorption	7/2/57

2 1	1/2/57 Fe-59	Ferrous citrate	2mCi	Intravenous injection of ferrous citrate to study plasma iron clearance and red cell incorporation in humans	12/:0/56
-----	--------------	--------------------	------	---	----------

* - Principal investigators unknown. ** - No supporting documents available for review. Information gleaned from copies of the license. Licensing staff also attempted to retrieve old documents from NUDOCS; however, no success.

Licensee: The University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma License No.: 35-03176-01, issued November 5, 1956 Docket No.: 030-03258

Amend No. or other Documentation	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
Letter July 1, Letter specifi development of medicine, the School and Uni should be auth quantities and byproduct mate	ied: Due to Fradioisotop Oklahoma Med iversity Hosp norized unspe fmultiple ty	es in ical ital cified					
byproduct material 10 12/30/66 3-83		3-83	Any	500 mCi authorization		Medical research, diag therapy Byproduct material for procedures and medical with labeled compounds doses may also be used State Penitentiary, Me Oklahoma, and Central Hospital, Norman, Okla Note: Central State He Oklahoma's Mental Hospital	r diagnostic I research s in tracer d at Oklahoma cAlester, State ahoma. ospital is

Letter June 3, 1964	
Question in letter to AEC:	
materials may be used in normal children less than 18-years of age as part of a research project. The question whether the AEC has any regulations or policy governing such use. We also wonder what maximum doses may be allowed in children by this use of radioactive material."	
No answer to these questions were found in the docket file.	
Letter March 11, 1966	Oklahoma State Penitentiary Inmate Volunteers
Request to broaden the scope of activities by working with radioactive tagged pharmacologic agents in an attempt to learn more about the metabolic fate of the compounds. Compounds to be ingested or injected	
Letter June 6, 1966	Oklahoma State Penitentiary Inmate
Study of the absorption, distribution, and metabolic fate of new and old pharmacologic agents.	
Note: AEC representative telephone note requesting confirmation that informed consent would be received from all subjects.	

Letter October 13, 1966	Oklahoma State Penitentiary Inmate Volunteers
Information specific to informed consent forms used at Oklahoma State Penitentiary and Oklahoma State Hospital.	Central State Hospital Volunteers
Letter June 14, 1974	Oklahoma State Penitentiary Inmate Volunteers
Letter provides information on the number and type of studies at the Oklahoma State Penitentiary.	Central State Hospital Volunteers
Seven projects in the clinical research lab unit "the work generally of these projects can all be classified as medical research, including some teaching activities."	

Licensee: National Aeronautics & Space Administration Johnson Space Center Houston, Texas License No.: 42-09388-03 Docket No.: 030-03264

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
9	1/22/74	Tc-99m	Pertechnetate & electrolytically labeled Human Serum Albumin	.025- .05mCi	Hoffler, Johnson	Cardiac studies on Skylab IV crew	1/3/74
7	7/27/72	S-35 H-3 Na-24 K-42				Modified authorization from Amendment # 5. Red cell mass, plasma volume, extracellular fluid volume, total body water and sodium and potassium space studies on volunteers over 21 years of age	6/15/72
		I-125				Modified authorization from Amendment # 6. Determine the occurrence & degree of bone mineral changes in volunteers over 21 years of age	
6	11/2/70	I-125	Sealed Source	4 sources @ 200mCi each	Vogel	Determine the occurrence & degree of bone mineral changes in the Apollo Crewman which might result from exposure to the weightless condition & short period of 1/6G alters these changes	9/24/70

5	7/9/70	S-35 H-3 Na-24 K-42	sulfate water chloride chloride	50uCi 150uCi 50uCi 100uCi	Fischer, Johnson	Study the effect of Apollo lunar missions & Tektite 100 foot ocean dive on red cell mass, plasma volume, extracellular fluid volume, total body water, and sodium and potassium space on volunteers over 21 years of age	5/14/70
1	9/11/68	C-14	glycine	50uCi	Fischer, Johnson	Measurements of selective age dependent erythrocyte destruction on volunteers	9/10/68
0	11/29/66	Cr-51	chromate	500uCi	Fischer, Johnson	Red blood cell mass & survival studies on volunteers	10/7/66
		Fe-59	Ferrous citrate	20uCi		Ferrokinetic studies on volunteers	
		I-125 /I-131	Human Serum Albumin	40uCi		Blood volume, plasma volume & cardiac output studies on volunteers	
		I-125 /I-131	Labeled Renal Function Compounds	200uCi		Renal function, and cardiac output studies on volunteers	

Licensee: Oklahoma Medical Research Foundation

Oklahoma City, Oklahoma License No.: 35-07464-03, issued March 31, 1958 Superseded License No. 35-7464-1, issued February 28, 1956

Docket No.: 030-02898

Amend No.	Date Issued	Isotope	Chemical form	Dose	PI	Purpose	Date of supporting document
9	8/6/62	Ca-47	chloride	10-20uCi	Reagan Bradford	Authorized use at McAlaster State Penitentiary. To evaluate the influence of several steroidal agents of the adrenal cortical type on the dynamics of calcium metabolism. Human subjects (prison volunteers) are maintained under balance conditions in the metabolic ward at McAlester	7/31/62
7	4/27/61	Ca-47	chloride	10-20uCi	Leonard Eliel	Study of calcium metabolism in patients with b one metastases from breast carcinoma.	4/12/61
4	6/2/60	Fe-59	Citrate globulinate	1mCi (possess -ion limit)	Leonard Eliel	Iron turnover studies "Ferro- kinetic studies in normal & diseased patients	4/26/60 & 2/29/60
3	3/28/60	Ca-45	chloride	10-30uCi	Leonard Eliel	Study of calcium metabolism in patients with bone metastases from breast cancer before & during administration of steroids & chemotherapeutic agents	2/29/60
		Mg-28	chloride	250-500 uCi		<u>In vitro</u> & lower animal studies and acute experiments in patients with bone cancer & leukemia to study magnesium & calcium removal from bone in response to parathyroid hormone	

2	11/10/59	C-14	Inulin- carbosylic acid	10mCi (possess -ion limit	Leonard Eliel	Measurement of glomerular filtration rate & extracellular fluid volume in normal & diseased patients	9/25/59 Approved by the AEC Medical Advisory Committee
		Н-3	Water	100mCi (possess -ion limit)		Measurement of total body water in normal & diseased patients.	
00	3/31/58	K-42	Chloride carbonate	250uCi	Leonard Eliel	To measure quantitatively tumor response from various medications and diet which are known to alter the growth rate of cancer tissue	2/14/58
		P-32	Soluble phosphate	250uCi		To determine the specific activity of P-32 in intracellular fractions & nucleic acids before & after administration of various agents	
		C-14	Sodium formate or Glycerine 2-C-14	lmCi		Metabolism studies in patients with leukemia or cancer	
		Rb-86	Chloride carbonate	200uCi		For use in patients with advanced breast carcinoma with known masses or metastases in order to find a reliable method of determining the effect of various drugs on the growth of cancer of the breast	
		Fe-59	Globulin complex	100uCi		Iron disappearance & reappearance rates are to be studied in human with leukemia and lymphosarcoma on various diets, and before & after chemotherapy determine the effects of these procedures on iron utilization & presumably hemoglobin synthesis	

NOTE: The format of the license changes in 1961 to a very broad authorization. We have been unable to identify any specific human research from that time forward. We have also been unable to locate the original license issued February 28, 1956 or the supporting documents from that time-frame.

Licensee Name	License # Application Date	Job#/Box#	Comments/Remarks
University of Cincinnati	34-6903-1 2-20-56	1722/094	2 entries (?2 files)
College of Medicine	34-6903-2 8-7-56	277/06	
	34-6903-3 11-19-56	277/06 1722/94	2 entries (?2 files)
College of Medicine	34-6903-4 6-4-57	0132/14 759/1	
	34-6903-5 3-28-58	227/12	A & B file in Oak Ridge, still listed as active license
	34-6903-6 4-21-59	1722/65	2 entries (?2 files)
	34-6903-7 5-25-59	1722/65 759/1	
	34-6903-8 6-19-70	277/13 759/1	sealed source - Cs-137
	34-6903-9 5-24-76		CO-60; found no info. on location - manual search or through database search done by Latravetta Lee (IRM)
Medical Center	34-6903-10 10-7-77	1193/12	teletherapy
	34-6903-11 12-04-80		found no info. on location - manual search or through database search done by Latravetta Lee
	34-6903-12 2-5-82	1659/11	
	34-6903-13 11-28-83		found no info. on location - manual search or through database search done by Latravetta Lee

Comments/Remarks					4 entries (?4 files)	denied - Warren F. Stubins, University of Cincinnati, College of Engineering	voided: Burnett Woods Park location	withdrawn - Nuclear Sciences and Engineering	withdrawn - Eugene L. Saenger		
Job#/Box#	1722/094	1722/047 759/1	1722/65 759/1	1722/65 759/1	1722/65 759/1	1722/047	1722/047	1722/047	1722/065		
License # Application Date	34-725-1 6-27-56	34-725-2 10-30-58	34-725-3 2-9-59	34-725-4 4-1-59	34-725-5 7-15-59	#10422	#31170	#35989	#40670 2/62		
Licensee Name	University of Cincinnati	Dept. of Chemistry									